GET THE APP

A case of Neuroleptic malignant syndrome associated with olanzapine and responsive to bromocryptine. | Abstract
Scholars Research Library

Scholars Research Library

A-Z Journals

+44 7389645282

Annals of Biological Research

Abstract

A case of Neuroleptic malignant syndrome associated with olanzapine and responsive to bromocryptine.

Author(s): Mrugank BP*, Hareesha RP*, Deepanjali M*, Mangala L*, Sibasish D*

Neuroleptic malignant syndrome (NMS) is the most serious of acute neurological side effects produced by antipsychotic medication, characterized by hyperthermia, rigidity, altered consciousness and autonomic dysfunction, the prevalence of which varies from 0.4-1.4%. NMS is usually seen in treatment with high potency typical antipsychotics and very rarely with atypical antipsychotics. However, NMS cases have been reported with risperidone, clozapine, olanzapine and quetiapine. The presentations of NMS have often varied, and we report atypicality in presentation of NMS due to olanzapine use.